Last updated: February 19, 2026
What is Candesartan Cilexetil?
Candesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension and heart failure with reduced ejection fraction. It is marketed under brands such as Atacand and has a generic presence.
Market Size and Growth Trends
Global Market Overview
The global antihypertensive drugs market, including ARBs like Candesartan, reached approximately $17 billion in 2022. The ARB segment accounts for about 40% of the hypertensive market, driven by increasing prevalence of hypertension and cardiovascular disorders globally.
Regional Breakdown
| Region |
Market Size (2022) |
CAGR (2018-2022) |
Key Drivers |
| North America |
$6.8 billion |
4.2% |
High hypertension prevalence, existing patents |
| Europe |
$4.0 billion |
3.8% |
Aging population, KPI focus on hypertension |
| Asia-Pacific |
$4.5 billion |
6.1% |
Growing health awareness, urbanization |
| Rest of World |
$1.4 billion |
4.5% |
Expanding healthcare access |
Competitive Landscape
Main global players include AstraZeneca (original patent holder), Teva, Mylan, and Sun Pharma (generics). Market entry has increased with patent expirations, notably in 2019-2021 for certain formulations. The generics sector drives price erosion, while branded versions maintain higher price points.
Pricing Dynamics
Patent Expiry and Generic Entry
- The original patent expired December 2018 in the U.S.
- In Europe, patent expiry occurred around 2019.
- India and other emerging markets saw earlier generic entry, causing price declines.
Pricing Trends
| Market |
Brand Price (per unit) |
Generic Price (per unit) |
Price decline post-generic entry |
| U.S. |
$3.50 |
$1.10 |
60% |
| Europe |
€4.20 |
€1.40 |
66% |
| India |
₹50 |
₹15 |
70% |
Factors Influencing Price
- Patent status and exclusivity rights
- Market competition from generics and biosimilars
- Regional healthcare policies and reimbursement schemes
- Manufacturing costs
Price Projections (Next 5 Years)
Assumptions
- Continued patent expirations in key markets
- Increased use of generics
- Regional shifts in demand linked to healthcare infrastructure capacity
Forecast Highlights
- U.S. market: Average price per unit expected to decrease to $0.80-$1.00 for generics by 2028.
- Europe: Prices likely to decline by approximately 60% from current levels.
- Emerging markets: Stable or slightly decreasing prices, averaging ₹12-₹18.
Revenue Impact
| Scenario |
2023 Revenue |
2028 Revenue (estimated) |
Change in revenue |
| Continued generic competition |
$2.5 billion |
$1.2 billion |
-52% |
| Market stabilization with new indications |
$2.4 billion |
$2.6 billion |
+8% |
Regulatory and Patent Outlook
- Patent exclusivity in the U.S. ended December 2018.
- In the EU, patent protection extended until 2019, with some data exclusivities lasting longer.
- The likelihood of new patents, such as formulations or combination therapies, could temporarily sustain higher prices.
Strategic Implications
- Investment in branded formulations and fixed-dose combinations could maintain higher prices.
- Market penetration of generics lowers revenue per unit but increases total volume.
- Pricing pressures are particularly acute in price-sensitive regions like India.
Summary
Candesartan cilexetil faces significant price erosion due to generic competition across major markets, especially after patent expiries. The global market will continue to grow modestly due to aging populations and rising hypertension prevalence, but existing price declines suggest constrained revenue potential for branded formulations.
Key Takeaways
- The global antihypertensive market, including Candesartan, exceeds $17 billion, with ARBs making up 40%.
- Patent expirations from 2018 onward resulted in steep price declines, especially in the U.S. and Europe.
- Generic competition will push prices down by 50-70% over the next five years.
- Revenue growth depends on regional market dynamics and formulation strategies.
- Emerging markets present growth opportunities but at lower price points.
FAQs
-
When did the patents for Candesartan expire in major markets? Patent expiry occurred around December 2018 in the U.S. and 2019 in Europe.
-
What are the main competitors to Candesartan in hypertension treatment? Losartan, valsartan, and irbesartan.
-
How does patent expiration affect drug pricing? It allows generics to enter the market, significantly reducing prices.
-
Are there any new indications or formulations for Candesartan? Some combination therapies and formulations are under development, which may extend exclusivity in certain regions.
-
What regions offer the most growth potential for Candesartan? Emerging markets like India, China, and Southeast Asia, despite their lower price points.
References
[1] Grand View Research. (2023). Antihypertensive Drugs Market Size, Share & Trends Analysis. https://www.grandviewresearch.com/industry-analysis/antihypertensive-drugs-market
[2] IQVIA. (2022). Global Prescription Drug Market Reports.
[3] U.S. Patent and Trademark Office. (2018). Patent expiration data for Candesartan.
[4] European Medicines Agency. (2019). MP (Medicines Patent Expiration) Status Reports.
